European Penny Stocks To Consider In August 2025
Top 10 Penny Stocks In Europe
Name
Share Price
Market Cap
Financial Health Rating
Mistral Iberia Real Estate SOCIMI (BME:YMIB)
€1.05
€22.87M
★★★★★☆
Maps (BIT:MAPS)
€3.34
€44.36M
★★★★★★
Angler Gaming (NGM:ANGL)
SEK3.60
SEK269.95M
★★★★★★
Angler Gaming (DB:0QM)
€0.37
€299.94M
★★★★★★
Cellularline (BIT:CELL)
€3.12
€65.81M
★★★★★☆
Fondia Oyj (HLSE:FONDIA)
€4.90
€18.32M
★★★★★★
Bredband2 i Skandinavien (OM:BRE2)
SEK3.255
SEK3.12B
★★★★☆☆
ForFarmers (ENXTAM:FFARM)
€4.60
€406.57M
★★★★★★
Deceuninck (ENXTBR:DECB)
€2.09
€288.55M
★★★★★★
Netgem (ENXTPA:ALNTG)
€0.934
€31.5M
★★★★★★
Click here to see the full list of 336 stocks from our European Penny Stocks screener.
Let's explore several standout options from the results in the screener.
ABIONYX Pharma
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: ABIONYX Pharma SA is a biotech company focused on discovering and developing therapies for renal and ophthalmological diseases, with a market cap of €64.01 million.
Operations: The company's revenue is primarily derived from its CRO Activity, which generated €4.55 million.
Market Cap: €64.01M
ABIONYX Pharma, a biotech company with a market cap of €64.01 million, is navigating challenges typical of penny stocks. Despite having more cash than debt and short-term assets exceeding liabilities, it remains pre-revenue with limited cash runway under a year. The company's revenue from CRO activities (€4.55 million) is insufficient to offset its unprofitability, as losses have increased by 18.6% annually over the past five years. While share dilution has been minimal and management is experienced, earnings are forecasted to decline by 33.8% per year for the next three years without expected profitability soon, reflecting high volatility in its stock price.
Navigate through the intricacies of ABIONYX Pharma with our comprehensive balance sheet health report here.
Gain insights into ABIONYX Pharma's future direction by reviewing our growth report.
High
Simply Wall St Financial Health Rating: ★★★★★★
Overview: High Co. SA offers consumer engagement chain solutions in France, Belgium, and Spain with a market cap of €91.99 million.
Operations: The company generates revenue of €146.38 million from its advertising segment.
Market Cap: €92M
High Co. SA, with a market cap of €91.99 million, demonstrates financial stability as its short-term assets exceed both short and long-term liabilities, and it has more cash than total debt. Despite high-quality earnings and no significant shareholder dilution recently, the company faces challenges such as negative earnings growth over the past year and declining profit margins. Although its debt is well covered by operating cash flow, the return on equity remains low at 9.7%. Earnings are expected to decline by an average of 13.9% annually over the next three years, indicating potential volatility in stock performance.
Take a closer look at High's potential here in our financial health report.
Explore High's analyst forecasts in our growth report.
Kudelski
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Kudelski SA, along with its subsidiaries, offers digital access and security solutions for digital television and interactive applications across various countries including Switzerland, the United States, France, Germany, and Austria; it has a market cap of CHF81.37 million.
Operations: The company's revenue is derived from three main segments: Digital TV, generating $227.83 million; Cybersecurity, contributing $108.47 million; and the Internet of Things, accounting for $47.43 million.
Market Cap: CHF81.37M
Kudelski SA, with a market cap of CHF81.37 million, is currently unprofitable but offers promising growth prospects in the digital access and security sectors. The company's strategic alliances, such as its partnership with Broadpeak to enhance streaming security for live sports content, highlight its focus on innovation and revenue protection. Despite past losses increasing at 20.3% per year over five years, Kudelski has improved its debt profile significantly from a 117% to 1.9% debt-to-equity ratio and maintains sufficient cash runway for over a year. Its seasoned management team further strengthens its potential for future stability and growth.
Click to explore a detailed breakdown of our findings in Kudelski's financial health report.
Understand Kudelski's earnings outlook by examining our growth report.
Summing It All Up
Dive into all 336 of the European Penny Stocks we have identified here.
Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTPA:ABNX ENXTPA:HCO and SWX:KUD.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Spirax Group (LON:SPX) Has Announced A Dividend Of £0.489
Spirax Group plc's (LON:SPX) investors are due to receive a payment of £0.489 per share on 14th of November. This makes the dividend yield about the same as the industry average at 2.3%. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Spirax Group's Projected Earnings Seem Likely To Cover Future Distributions While it is always good to see a solid dividend yield, we should also consider whether the payment is feasible. Prior to this announcement, Spirax Group's dividend made up quite a large proportion of earnings but only 52% of free cash flows. In general, cash flows are more important than earnings, so we are comfortable that the dividend will be sustainable going forward, especially with so much cash left over for reinvestment. Looking forward, earnings per share is forecast to rise by 51.7% over the next year. Assuming the dividend continues along the course it has been charting recently, our estimates show the payout ratio being 54% which brings it into quite a comfortable range. View our latest analysis for Spirax Group Spirax Group Has A Solid Track Record Even over a long history of paying dividends, the company's distributions have been remarkably stable. The dividend has gone from an annual total of £0.669 in 2015 to the most recent total annual payment of £1.65. This implies that the company grew its distributions at a yearly rate of about 9.4% over that duration. The dividend has been growing very nicely for a number of years, and has given its shareholders some nice income in their portfolios. Dividend Growth May Be Hard To Achieve Some investors will be chomping at the bit to buy some of the company's stock based on its dividend history. Unfortunately things aren't as good as they seem. Unfortunately, Spirax Group's earnings per share has been essentially flat over the past five years, which means the dividend may not be increased each year. Our Thoughts On Spirax Group's Dividend Overall, we always like to see the dividend being raised, but we don't think Spirax Group will make a great income stock. The company is generating plenty of cash, but we still think the dividend is a bit high for comfort. Overall, we don't think this company has the makings of a good income stock. Companies possessing a stable dividend policy will likely enjoy greater investor interest than those suffering from a more inconsistent approach. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. For example, we've picked out 1 warning sign for Spirax Group that investors should know about before committing capital to this stock. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
17 minutes ago
- Yahoo
Liverpool take CHARGE of battle for Premier League star
Liverpool are firmly in the driving seat for one Premier League star. The Reds hold the cards as crunch time nears. There are now around two weeks left of the summer transfer window and Liverpool are far from done. That's despite possibly the busiest window we've ever seen from the Reds. Richard Hughes and co. have set about overhauling the first-team squad. We've had record-breaking arrivals, high-profile exits, and a lot of drama, honestly. Shop the LFC Store LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! 🔴 Shop the LFC 2025/26 adidas home range Liverpool have changed their defence significantly and their attack has been reshaped around Florian Wirtz and Hugo Ekitiké. And yet both areas are set to see moe changes. Alexander Isak is the big one up top, of course. Liverpool are desperate to sign the Swede and would pay a British transfer record fee in order to get it done. Defence, though, isn't sorted either. Liverpool are on the verge of signing Giovanni Leoni from Parma - one of the best young talents in Europe right now. It's a deal that should lock down the future of their defence. But it also hands them the initiative in another centre-back race. 🔴 Shop the LFC 2025/26 adidas away range Liverpool want Marc Guehi Fabrizio Romano is adamant that Liverpool still want to sign Marc Guehi despite the deal for Leoni. Crystal Palace are open to selling their captain as he's now within the final year of his contract. In fact, Palace are actively looking to sell. Chairman Steve Parish admitted as much this week - the Eagles can't afford to let Guehi leave for free in 2026. It created a game of chicken, essentially. Palace want a sizeable fee despite the risk of nothing in a year. Liverpool want a discounted fee because of the risk of nothing in a year. Whose nerve would hold? Well, Liverpool's as it turns out. Palace's power in negotiations came from Liverpool needing a new centre-back. Jarell Quansah left the club this summer, leaving the Reds short. Leoni, however, now fills the void left by Quansah. It means the squad doesn't actually need Guehi right now - Liverpool would just like to have him early. A week ago, Palace knew they could hold firm on their fee and Liverpool may be forced to pay it in order to avoid heading into the upcoming season with only three centre-backs. We've seen that story before, after all, and it ends horrendously. But now Liverpool are likely fine with waiting on Guehi. They've got four centre-backs and now it's Palace who are the most eager to get a deal done. It should see the asking price drop as we get closer to the end of the window and closer to Guehi leaving for free. Advantage Liverpool.
Yahoo
17 minutes ago
- Yahoo
INDUS Holding Second Quarter 2025 Earnings: EPS: €0.50 (vs €0.83 in 2Q 2024)
INDUS Holding (ETR:INH) Second Quarter 2025 Results Key Financial Results Revenue: €438.2m (up 2.0% from 2Q 2024). Net income: €12.3m (down 43% from 2Q 2024). Profit margin: 2.8% (down from 5.0% in 2Q 2024). The decrease in margin was driven by higher expenses. EPS: €0.50 (down from €0.83 in 2Q 2024). AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. All figures shown in the chart above are for the trailing 12 month (TTM) period INDUS Holding Earnings Insights Looking ahead, revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Industrials industry in Europe. Performance of the market in Germany. The company's shares are down 5.3% from a week ago. Risk Analysis Before we wrap up, we've discovered 2 warning signs for INDUS Holding (1 is potentially serious!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
